Business
AGM statement & positive Q1 trading update
EKF Diagnostics Holdings plc has provided a positive trading update ahead of its AGM, confirming that trading for the year ending December 31, 2026, remains in line with management expectations. The company reported a cash position of £15.0 million as of May 8, with £2.1 million restricted in its Russian subsidiary, and continues to invest in growth initiatives and its share buyback program. Commercial traction for Hematology is strong, and β-HB sales in Life Sciences have exceeded expectations, with contract fermentation services showing steady improvement. EKF is on track to deliver revenue and adjusted EBITDA growth for FY 2026 in line with market expectations of £54.6 million and £13.6 million respectively. Disclaimer*
About this update from Ekf Diagnostics Holdings Plc
EKF Diagnostics Holdings plc ("EKF" or the "Company") AGM Statement & Positive Q1 Trading update EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, provides an update to shareholders ahead of its Annual General Meeting ('AGM') today at Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD at 11.00 am. Executive Chair's AGM statement We are very pleased that trading to date for the year ended 31 December 2026 (" FY 2026") remains in-line with management expectations. As usual, we will provide an unaudited trading update for first six months of the current financial year ("H1 2026") at the end of July. The completion of the first year of our Five-Year Strategic Development plan has firmly re-established the business with a simplified product offering, a greater commercial focus on the areas of strategic importance and an expanded marketing team to drive further organic growth. Operational cash generation continues to be very strong alongside the continued internal investment for growth and the ongoing share buyback programme. Cash position as of 8 May is £15.0m, with £2.1m held by our Russian subsidiary and subject to regulatory restrictions, and we will continue to invest in areas that will further build on our growth strategy, and deliver long term shareholder value. Commercial traction for Hematology remains strong with good ongoing instrument placement and increased consumable pull-through as expected. Within the Life Sciences division, β-HB sales have performed above management expectations and the pipeline and prospects for our contract fermentation services continues to grow showing continued steady improvement. We remain excited about the prospects for the business and are on track to deliver growth at the revenue and adjusted EBITDA 1 levels for FY 2026 in-line with market expectations 2 . 1 adjusted earnings before interest, tax, depreciation and amortisation, share-based payments and exceptional items ² Management understands consensus revenue and Adjusted EBITDA forecasts for FY 2026 to be £54.6m and £13.6m respectively. EKF Diagnostics Holdings plc www.ekfdiagnostics.com Julian Baines, Executive Chair / Gavin Jones, Chief Executive Officer via Walbrook PR Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000 Phil Davies / Patrick Weaver Walbrook PR Limited Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
View stock analysis, news, and events for Ekf Diagnostics Holdings Plc